Innate immunity in the lung: How epithelial cells fight against respiratory pathogens

European Respiratory Journal

Volumn 23, Issue 2, 2004, Pages 327-333

  Bals, R ^a   Hiemstra, P S ^b  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antimicrobial peptide; Cathelicidins; Defensins; Epithelium; Infections; Innate immunity

Indexed keywords

CHEMOKINE; CYTOKINE; PEPTIDE; TOLL LIKE RECEPTOR;

AIR; CYTOKINE PRODUCTION; ENVIRONMENTAL EXPOSURE; HOST RESISTANCE; HUMAN; INFLAMMATION; INHALATION; LUNG ALVEOLUS EPITHELIUM; MICROORGANISM; MUCOSAL IMMUNITY; PRIORITY JOURNAL; RESPIRATORY EPITHELIUM; RESPIRATORY TRACT INFECTION; RESPIRATORY TRACT MUCOSA; REVIEW; WOUND HEALING;

ALPHA-DEFENSINS; ANIMALS; CHEMOKINES; CYTOKINES; HUMANS; IMMUNITY, NATURAL; MEMBRANE GLYCOPROTEINS; RECEPTORS, CELL SURFACE; RESPIRATORY MUCOSA; RESPIRATORY TRACT INFECTIONS; TOLL-LIKE RECEPTORS;

EID: 1042269503     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.03.00098803     Document Type: Review

References (80)

1. Medzhitov R, Janeway CA Jr. Innate immunity: impact on the adaptive immune response. Curr Opin Immunol 1997; 9: 4-9.
2. Diamond G, Legarda D, Ryan LK. The innate immune response of the respiratory epithelium. Immunol Rev 2000; 173: 27-38.
3. Holgate ST, Lackie P, Wilson S, Roche W, Davies D. Bronchial epithelium as a key regulator of airway allergen sensitization and remodeling in asthma. Am J Respir Crit Care Med 2000; 162: S113-S117.
4. Lemaitre B, Reichhart JM, Hoffmann JA. Drosophila host defense: Differential induction of antimicrobial peptide genes after infection by various classes of microorganisms. Proc Natl Acad Sci Usa 1997; 94: 14614-14619.
5. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003; 21: 335-376.
6. Duits LA, Nibbering PH, van Strijen E, et al. Rhinovirus increases human [beta]-defensin-2 and -3 mRNA expression in cultured bronchial epithelial cells. FEMS Immunology and Medical Microbiology 2003; 38: 59-64.
7. Becker MN, Diamond G, Verghese MW, Randell SH. CD14-dependent lipopolysaccharide-induced beta-defensin-2 expression in human tracheobronchial epithelium. J Biol Chem 2000; 275: 29731-29736.
8. Jaumann F, Unterberger P, Villena H, Welsch U, Vogelmeier C, Bals R. Differential expression and regulation of Toll-like receptors 1-9 in human airway epithelium. Am J Respir Crit Care Med 163, A379. 2001.
9. Poltorak A, He X, Smirnova I, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998; 282: 2085-2088.
10. Qureshi ST, Lariviere L, Leveque G, et al. Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr-4). J Exp Med 1999; 189: 615-625.
11. Hoshino K, Takeuchi O, Kawai T, et al. Cutting Edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol 1999; 162: 3749.
12. Agnese DM, Calvano JE, Hahm SJ, et al. Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. J Infect Dis 2002; 186: 1522-1525.
13. Dentener MA, Vreugdenhil ACE, Hoet PHM, et al. Production of the acute-phase protein lipopolysaccharide-binding protein by respiratory type II epithelial cells. Implications for local defense to bacterial endotoxins. Am J Respir Cell Mol Biol 2000; 23: 146.
14. Underhill DM, Ozinsky A. Toll-like receptors: key mediators of microbe detection. Curr Opin Immunol 2002; 14: 103-110.
15. Werts C, Tapping RI, Mathison JC, et al. Leptospiral lipopolysaccharide activates cells through a TLR2-dependent mechanism. Nat Immunol 2001; 2: 346-352.
16. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001; 413: 732-738.
17. Gern JE, French DA, Grindle KA, et al. Double-stranded RNA induces the synthesis of specific chemokines by bronchial epithelial cells. Am J Respir Cell Mol Biol 2003; 28: 731.
18. Akhtar M, Watson JL, Nazli A, McKay DM. Bacterial DNA evokes epithelial IL-8 production by a MAPK-dependent, NFkappaB-independent pathway. FASEB J: 2003: 1319-1321.
19. Guillot L, Balloy V, McCormack FX, et al. Cutting edge: the immunostimulatory activity of the lung surfactant protein-A involves Toll-like receptor 4. J Immunol 2002; 168: 5989-5992.
20. Biragyn A, Ruffini PA, Leifer CA, et al. Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science 2002; 298: 1025-1029.
21. Ganz T. Immunology: Versatile Defensins. Science 2002; 298: 977.
22. Birchler T, Seibl R, Buchner K, et al. Human Toll-like receptor 2 mediates induction of the antimicrobial peptide human beta-defensin 2 in response to bacterial lipoprotein. Eur J Immunol 2001; 31: 3131-3137.
23. Kawai K, Shimura H, Minagawa M, et al. Expression of functional Toll-like receptor 2 on human epidermal keratinocytes. J Dermatol Sci 2002; 30: 185-194.
24. Imasato A, Desbois-Mouthon C, Han J, et al. Inhibition of p38 MAPK by glucocorticoids via induction of MAPK phosphatase-1 enhances nontypeable Haemophilus influenzae-induced expression of toll-like receptor 2. J Biol Chem 2002; 277: 47444-47450.
25. Wolfs TG, Buurman WA, Van Schadewijk A, et al. IFN-gamma and TNF-alpha Mediated Up-Regulation During Inflammation. J Immunol 2002; 168: 1286-1293.
26. O'Neill LAJ, Fitzgerald KA, Bowie AG. The Toll-IL-1 receptor adaptor family grows to five members. Trends in Immunology 2003; 24: 287-290.
27. Yeh WC, Chen NJ. Another toll road. Nature 2003; 424: 736-737.
28. Davies DE. The bronchial epithelium in chronic and severe asthma. Curr Allergy Asthma Rep 2001; 1: 127-133.
29. Hiemstra PS. Epithelial antimicrobial peptides and proteins: their role in host defence and inflammation. Paediatr Respir Rev 2001; 2: 306-310.
30. Schutte BC, McCray PB Jr. [beta]-defensins in lung host defense. Annu Rev Physiol 2002; 64: 709-748.
31. Harder J, Meyer-Hoffert U, Teran LM, et al. Mucoid Pseudomonas aeruginosa, TNF-alpha, and IL-1beta, but not IL-6, induce human beta-defensin-2 in respiratory epithelia. Am J Respir Cell Mol Biol 2000; 22: 714-721.
32. O'Neil DA, Porter EM, Elewaut D, et al. Expression and regulation of the human beta-defensins hBD-1 and hBD-2 in intestinal epithelium. J Immunol 1999; 163: 6718-6724.
33. Tsutsumi-Ishii Y, Nagaoka I. NF-kappa B-mediated transcriptional regulation of human beta-defensin-2 gene following lipopolysaccharide stimulation. J Leukoc Biol 2002; 71: 154-162.
34. Krisanaprakornkit S, Kimball JR, Dale BA. Regulation of human beta-defensin-2 in gingival epithelial cells: the involvement of mitogen-activated protein kinase pathways, but not the NF-kappaB transcription factor family. J Immunol 2002; 168: 316-324.
35. Takahashi A, Wada A, Ogushi K, et al. Production of beta-defensin-2 by human colonic epithelial cells induced by Salmonella enteritidis flagella filament structural protein. FEBS Lett 2001; 508: 484-488.
36. Garcia JR, Jaumann F, Schulz S, et al. Identification of a novel, multifunctional beta-defensin (human beta- defensin 3) with specific antimicrobial activity. Its interaction with plasma membranes of Xenopus oocytes and the induction of macrophage chemoattraction. Cell Tissue Res 2001; 306: 257-264.
37. Hiratsuka T, Nakazato M, Date Y, et al. Identification of human beta-defensin-2 in respiratory tract and plasma and its increase in bacterial pneumonia. Biochem Biophys Res Commun 1998; 249: 943-947.
38. Bals R, Weiner DJ, Meegalla RL, Accurso F, Wilson JM. Salt-independent abnormality of antimicrobial activity in cystic fibrosis airway surface fluid. Am J Respir Cell Mol Biol 2001; 25: 21-25.
39. Ashitani J, Mukae H, Hiratsuka T, et al. Plasma and BAL Fluid Concentrations of Antimicrobial Peptides in Patients With Mycobacterium avium- intracellulare Infection. Chest 2001; 119: 1131-1137.
40. Ashitani J, Mukae H, Hiratsuka T, et al. Elevated Levels of {alpha}:-Defensins in Plasma and BAL Fluid of Patients With Active Pulmonary Tuberculosis. Chest 2002; 121: 519-526.
41. Soong LB, Ganz T, Ellison A, Caughey GH. Purification and characterization of defensins from cystic fibrosis sputum. Inflamm Res 1997; 46: 98-102.
42. Ashitani J, Mukae H, Nakazato M, et al. Elevated concentrations of defensins in bronchoalveolar lavage fluid in diffuse panbronchiolitis. Eur Respir J 1998; 11: 104-111.
43. Ihi T, Nakazato M, Mukae H, Matsukura S. Elevated concentrations of human neutrophil peptides in plasma, blood, and body fluids from patients with infections. Clin Infect Dis 1997; 25: 1134-1140.
44. Panyutich AV, Hiemstra PS, van Wetering S, Ganz T. Human neutrophil defensin and serpins form complexes and inactivate each other. Am J Respir Cell Mol Biol 1995; 12: 351-357.
45. Mukae H, Iiboshi H, Nakazato M, et al. Raised plasma concentrations of {alpha}-defensins in patients with idiopathic pulmonary fibrosis. Thorax 2002; 57: 623-628.
46. Schaller-Bals S, Schulze A, Bals R. Increased Levels of Antimicrobial Peptides in Tracheal Aspirates of Newborn Infants during Infection. Am J Resp Crit Care Med 2002; 165: 992-995.
47. Singh PK, Jia HP, Wiles K, et al. Production of beta-defensins by human airway epithelia. Proc Natl Acad Sci U S A 1998; 95: 14961-14966.
48. Hiratsuka T, Mukae H, Iiboshi H, et al. Increased concentrations of human {beta}-defensins in plasma and bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis. Thorax 2003; 58: 425-430.
49. Agerberth B, Grunewald J, Castanos-Velez E, et al. Antibacterial components in bronchoalveolar lavage fluid from healthy individuals and sarcoidosis patients. Am J Respir Crit Care Med 1999; 160: 283-290.
50. Liu L, Roberts AA, Ganz T. By IL-1 signaling, monocyte-derived cells dramatically enhance the epidermal antimicrobial response to lipopolysaccharide. J Immunol 2003; 170: 575-580.
51. Tsutsumi-Ishii Y, Nagaoka I. Modulation of human beta-defensin-2 transcription in pulmonary epithelial cells by lipopolysaccharide-stimulated mononuclear phagocytes via proinflammatory cytokine production. J Immunol 2003; 170: 4226-4236.
52. Sorensen OE, Cowland JB, Theilgaard-Monch K, et al. Wound healing and expression of antimicrobial peptides/polypeptides in human keratinocytes, a consequence of common growth factors. J Immunol 2003; 170: 5583-5589.
53. Schauber J, Svanholm C, Termen S, et al. Expression of the cathelicidin LL-37 is modulated by short chain fatty acids in colonocytes: relevance of signalling pathways. Gut 2003; 52: 735-741.
54. Hase K, Eckmann L, Leopard JD, Varki N, Kagnoff MF. Cell differentiation is a key determinant of cathelicidin LL-37/human cationic antimicrobial protein 18 expression by human colon epithelium. Infect Immun 2002; 70: 953-963.
55. Koczulla AR, Bals R. Antimicrobial peptides: current status and therapeutic potential. Drugs 2003; 63: 389-406.
56. Wilson CL, Ouellette AJ, Satchell DP, et al. Regulation of intestinal alpha-defensin activation by the metalloproteinase matrilysin in innate host defense. Science 1999; 286: 113-117.
57. Moser C, Weiner DJ, Lysenko E, et al. beta-Defensin 1 contributes to pulmonary innate immunity in mice. Infect Immun 2002; 70: 3068-3072.
58. Nizet V, Ohtake T, Lauth X, et al. Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature 2001; 414: 454-457.
59. Bals R, Weiner DJ, Meegalla RL, Wilson JM. Transfer of a cathelicidin peptide antibiotic gene restores bacterial killing in a cystic fibrosis xenograft model. J Clin Invest 1999; 103: 1113-1117.
60. Bals R, Griese M. Kleinmolekulare antimikrobielle Substanzen der Atemwegsfluessigkeit. In: Reinhardt D, Goetz M, Kraemer R, Schoeni M, editors. Mukoviszidose. Heidelberg, Springer, 1999.
61. Salzman NH, Ghosh D, Huttner KM, Paterson Y, Bevins CL. Protection against enteric salmonellosis in transgenic mice expressing a human intestinal defensin. Nature 2003; 422: 522-526.
62. Smith JJ, Travis SM, Greenberg EP, Welsh MJ. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 1996; 85: 229-236.
63. Goldman MJ, Anderson GM, Stolzenberg ED, et al. Human β-defensin-1 is a salt-sensitive antibiotic in the lung that is inactivated in cystic fibrosis. Cell 1997; 88: 553-560.
64. Aarbiou J, Rabe KF, Hiemstra PS. Role of defensins in inflammatory lung disease. Ann Med 2002; 34: 96-101.
65. Cole AM, Tahk S, Oren A, et al. Determinants of Staphylococcus aureus nasal carriage. Clin Diagn Lab Immunol 2001; 8: 1064-1069.
66. Matsushita I, Hasegawa K, Nakata K, et al. Genetic variants of human beta-defensin-1 and chronic obstructive pulmonary disease. Biochem Biophys Res Commun 2002; 291: 17-22.
67. van Wetering S, Mannesse-Lazeroms SPG, Van Sterkenburg MAJA, et al. Effect of defensins on IL-8 synthesis in airway epithelial cells. Am J Physiol (Lung Cell Mol Physiol ) 1997; 272: L888-L896.
68. Chertov O, Michiel DF, Xu L, et al. Identification of defensin-1, defensin-2 and CAP37/azurocidin as T-cell chemoattractant proteins released from interleukin-8-stimulated neutrophils. J Biol Chem 1996; 271: 2935-2940.
69. Yang D, Chen Q, Chertov O, Oppenheim JJ. Human neutrophil defensins selectively chemoattract naive T and immature dendritic cells. J Leukoc Biol 2000; 68: 9-14.
70. Territo MC, Ganz T, Selsted ME, Lehrer R. Monocyte-chemotactic activity of defensins from human neutrophils. J Clin Invest 1989; 84: 2017-2020.
71. Lillard JW Jr, Boyaka PN, Chertov O, Oppenheim JJ, McGhee JR. Mechanisms for induction of acquired host immunity by neutrophil peptide defensins. Proc Natl Acad Sci U S A 1999; 96: 651-656.
72. Yang D, Chertov O, Bykovskaia SN, et al. Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science 1999; 286: 525-528.
73. Garcia J-RC, Krause A, Schulz S, et al. Human beta-defensin 4: a novel inducible peptide with a specific salt-sensitive spectrum of antimicrobial activity. FASEB J 2001; 15: 1819-1821.
74. Yang D, Chen Q, Schmidt AP, et al. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utlizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. JEM 2000; 192: 1069-1074.
75. Niyonsaba F, Someya A, Hirata M, Ogawa H, Nagaoka I. Evaluation of the effects of peptide antibiotics human beta-defensins- 1/-2 and LL-37 on histamine release and prostaglandin D(2) production from mast cells. Eur J Immunol 2001; 31: 1066-1075.
76. Durr M, Peschel A. Chemokines meet defensins: the merging concepts of chemoattractants and antimicrobial peptides in host defense. Infect Immun 2002; 70: 6515-6517.
77. Aarbiou J, Verhoosel RM, van Wetering S, et al. Neutrophil defensins enhance lung epithelial wound closure and mucin gene expression in vitro. Am J Resp Cell Mol Biol 2004; (in press).
78. Frye M, Bargon J, Gropp R. Expression of human beta-defensin-1 promotes differentiation of keratinocytes. J Mol Med 2001; 79: 275-282.
79. Heilborn JD, Nilsson MF, Kratz G, et al. The cathelicidin anti-microbial peptide LL-37 is involved in re- epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. J Invest Dermatol 2003; 120: 379-389.
80. Koczulla R, von Degenfeld G, Kupatt C, et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest 2003; 111: 1665-1672.